---
title: FDA vs. MDR: Fundamental Differences in Medical Device Regulation
description: The structural differences between FDA and EU MDR — regulation vs guidance, notified body vs agency, classification logic, evidence and post-market philosophy.
authors: Tibor Zechmeister, Felix Lenhard
category: FDA & International Market Access
primary_keyword: FDA vs MDR fundamental differences
canonical_url: https://zechmeister-solutions.com/en/blog/fda-vs-mdr-fundamental-differences
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# FDA vs. MDR: Fundamental Differences in Medical Device Regulation

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **FDA and EU MDR regulate the same industry through structurally different machines. MDR is a directly applicable regulation enforced through independent notified bodies; FDA is a statute and codified regulations enforced through a single federal agency. They differ in how they classify devices, what evidence they expect, and how they police the market after launch. The practical consequence for a startup: a dual-market strategy is not one product with two labels — it is two regulatory lifecycles that must be planned together from day one.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- MDR is an EU regulation — directly applicable law in every member state. FDA operates under the Federal Food, Drug, and Cosmetic Act and the Code of Federal Regulations.
- MDR conformity assessment is performed by independent notified bodies designated by member state authorities. FDA review is performed centrally by a single federal agency.
- Classification logic differs: MDR uses 22 rules in Annex VIII to place devices in Class I, IIa, IIb, or III. 
- Evidence philosophy differs: MDR requires a continuously updated Clinical Evaluation; FDA's dominant pathway (510(k)) pivots on substantial equivalence to a predicate device.
- Post-market philosophy differs: MDR builds PMS, PSUR, PMCF, and vigilance into a continuous cycle under Art. 83-92. FDA relies on MDRs, post-approval studies, and MDUFA-driven inspections.
- Neither system is "lighter." They are different machines with different load-bearing points. A startup that treats FDA as MDR-minus will miss what FDA actually checks, and vice versa.

## Why this matters (Hook)

The most expensive mistake Tibor sees in founders targeting both EU and US markets is not a missed study or a mistranslated label. It is a strategic assumption: that one regulatory file, built to the stricter of the two systems, will satisfy both. It does not. The two systems are stricter in different places, about different things, through different mechanisms.

A startup optimised its Class IIa software-as-a-medical-device around MDR Annex VIII Rule 11, with a thorough clinical evaluation under MDR Art. 61 and a PMS system designed around PSURs. It assumed FDA would be simpler because its intended use description was modest. FDA looked at the same device and asked for substantial equivalence to a predicate — which the team had never researched — and a premarket pathway discussion the team had never initiated. Eighteen months of EU-optimised work did not translate into a US submission. The reverse also happens: teams build a tight 510(k) package and discover that their predicate strategy is irrelevant to MDR, where clinical evaluation must stand on its own data.

Understanding the structural differences is not an academic exercise. It is how you decide, at the start, whether you are building one device with two regulatory lifecycles, two products for two markets, or one market first and the other later.

## What MDR actually says (Surface)

MDR is Regulation (EU) 2017/745. "Regulation" in EU law has a specific meaning: it is directly applicable in every member state without requiring national transposition. When MDR says a manufacturer must do something, that requirement is law in Austria, Germany, France, and every other member state simultaneously, in the same wording.

**Article 5** — Placing on the market and putting into service — sets the primary obligation: a device may only be placed on the EU market if it complies with the regulation when duly supplied and properly installed, maintained and used in accordance with its intended purpose.

**Annex VIII** — Classification rules — contains 22 rules organised by device type (non-invasive, invasive, active, special rules). A manufacturer applies the rules to determine whether the device is Class I, IIa, IIb, or III. Higher classes require higher-intensity conformity assessment.

**Annexes IX, X, and XI** — Conformity assessment routes. Annex IX is the full quality management system route based on EN ISO 13485:2016+A11:2021. Annex X is type examination. Annex XI is production quality assurance. The class and type of device determine which route or routes apply.

The enforcement architecture is distributed. The European Commission sets the rules. Member state competent authorities designate notified bodies. Notified bodies assess conformity. Manufacturers self-declare for Class I non-sterile, non-measuring, non-reusable surgical instruments; everything else involves a notified body for some part of the assessment. 

Now the FDA structural picture, at the level a founder needs for strategic planning:

The US Food and Drug Administration regulates medical devices under the Federal Food, Drug, and Cosmetic Act. Implementing regulations live in Title 21 of the Code of Federal Regulations. Classification is organised by product code in 21 CFR parts 862-892, and devices are assigned to Class I, II, or III based on the level of control necessary to provide reasonable assurance of safety and effectiveness. 

The dominant premarket pathway is the 510(k), a submission demonstrating substantial equivalence to a legally marketed predicate device. Where no predicate exists but risk is low to moderate, De Novo classification creates a new device type. For high-risk devices, premarket approval (PMA) is required.

Unlike the EU, there are no notified bodies. FDA itself is the reviewer, inspector, and enforcer. Quality system requirements have historically lived in 21 CFR Part 820 (the Quality System Regulation) and are transitioning to harmonisation with ISO 13485 under the Quality Management System Regulation (QMSR).

## A worked example (Test)

Take a Class IIa SaMD — an app that analyses wearable-derived data to flag potential atrial fibrillation for clinician review. A startup wants both markets.

**EU pathway under MDR.** Annex VIII Rule 11 drives classification. The device provides information used to take decisions with therapy or diagnostic purposes, so the classification discussion quickly moves to whether the decisions could cause serious deterioration of health — driving it to Class IIa or higher. Conformity assessment under Annex IX involves a notified body reviewing the QMS (built on EN ISO 13485:2016+A11:2021) and the technical documentation including a clinical evaluation under MDR Art. 61 and Annex XIV. The clinical evaluation must stand on its own clinical data — own investigation, equivalence to another device with access to that device's data, or sufficient published evidence meeting MDCG 2020-5 standards.

**US pathway under FDA.** The starting question is predicate. Is there a legally marketed 510(k)-cleared device with the same intended use and similar technological characteristics? If yes, the pathway is 510(k) with a substantial equivalence argument backed by performance data — often bench and clinical — comparing the new device to the predicate. If no predicate exists but the risk profile fits, De Novo classification is the route. The clinical evaluation concept does not exist in the same form: FDA asks for evidence sufficient to support the specific claims, calibrated to the predicate strategy.

The team can reuse parts of the work — algorithm validation, software lifecycle under EN 62304, cybersecurity, usability data — but cannot reuse the regulatory spine. The MDR clinical evaluation does not translate into a 510(k) substantial equivalence argument. The 510(k) predicate analysis does not translate into an MDR clinical evaluation. The QMS can be built once to EN ISO 13485 and carry weight in both markets, especially as QMSR aligns US expectations with ISO 13485.

Planning that reuse from day one — what is common, what is parallel, what is sequential — is the dual-market strategy. Not doing so is how startups spend twice for half the coverage.

## The Subtract to Ship playbook (Ship)

Subtract to Ship for dual-market regulatory strategy is about refusing to do work twice and refusing to pretend one system answers the other.

**1. Decide your lead market on the basis of patients, reimbursement, and commercial geography.** Not on which regulation is "easier." Both are demanding. Pick where the commercial case is strongest and the regulatory timeline matches your capital plan.

**2. Build the QMS once.** EN ISO 13485:2016+A11:2021 is the common foundation. With QMSR, FDA expectations increasingly align with ISO 13485. Build one QMS, scale it to both markets from day one, and avoid parallel quality systems.

**3. Map evidence once, use it twice where possible.** Bench data, software verification, usability evaluations, cybersecurity documentation — these can be authored once with both markets in mind. Clinical evidence needs explicit planning: what works for MDR Art. 61, what works for FDA substantial equivalence, and what needs separate studies.

**4. Do not confuse substantial equivalence with clinical evaluation.** They are different intellectual exercises. One compares to a predicate; the other builds an independent case. A team that files MDR first and assumes FDA is a formality will stumble on predicate research they never did. A team that files FDA first and assumes CE is a formality will stumble on clinical data they never generated.

**5. Plan post-market architectures in parallel.** MDR Art. 83-92 builds PMS, PSUR, PMCF, and vigilance into a continuous cycle. FDA post-market relies on MDRs, post-approval studies (for PMA), and inspection-driven oversight. Build a single post-market data system that produces both streams.

**6. Do not wait for "regulatory alignment."** IMDRF produces useful harmonisation guidance, but the machines remain structurally different. Plan for duality, not convergence.

**7. Name owners for each market.** The EU PRRC under MDR Art. 15 is a named individual. The US regulatory affairs function is a named individual. Even in a small team, "the CEO does regulatory for both" is not a strategy; it is a failure mode.

The subtraction: eliminate work that exists only because you treated one system as a shadow of the other. Keep the work that is genuinely needed by each machine, and recognise that the two together are less than twice the work of one done properly.

## Reality Check

1. Have you chosen a lead market on commercial grounds, not on perceived regulatory ease?
2. Is your QMS built to EN ISO 13485 with awareness of QMSR expectations for the US?
3. Have you researched potential 510(k) predicates for your US pathway, even if your lead market is EU?
4. Is your MDR clinical evaluation plan independent of any substantial equivalence argument?
5. Do you have a named individual accountable for each regulatory pathway?
6. Does your evidence plan distinguish what can be reused across markets from what must be generated separately?
7. Is your post-market data architecture designed to feed both MDR PMS/PSUR and FDA MDR reporting?
8. If a board member asked "why both markets, in what order, at what cost, on what timeline," could you answer in under five minutes with specifics?

## Frequently Asked Questions

**Is FDA really faster than MDR?**
Sometimes, for specific device types and specific pathways. 510(k) clearance for a well-predicated device can be faster than a first MDR notified body review under Annex IX. But the comparison is misleading without considering the total work, including clinical evidence generation and post-market obligations.

**Can I use the same clinical data for both submissions?**
Sometimes. Data from a well-designed clinical investigation can support both an MDR clinical evaluation and an FDA submission, provided the study design anticipated both uses. Retrofitting a single-market study for the other market is often inadequate.

**Does QMSR mean FDA and MDR are now the same on quality?**
QMSR aligns FDA quality system expectations with ISO 13485, reducing duplication. It does not eliminate differences in documentation expectations, inspection style, or management responsibilities.

**Is the notified body the EU equivalent of FDA?**
Structurally, no. FDA is a single federal agency with regulatory, review, and enforcement authority. A notified body is an independent conformity assessment body designated by a member state authority, reviewing technical documentation and QMS but not itself a regulator. The EU regulator is the European Commission plus member state competent authorities.

**Which market should a European startup target first?**
Usually EU, because the team, the clinical sites, and the initial commercial traction are local. But the decision depends on reimbursement dynamics, investor expectations, and where the predicate and competitive landscape are most favourable.

**What changes for AI/ML devices?**
Both systems are evolving. MDR engages through Annex VIII Rule 11 and the EU AI Act layered on top. FDA has its own AI/ML guidance and predetermined change control plan framework. Neither is settled. Dual-market AI strategy requires explicit tracking of both policy streams.

## Related reading
- [MDR vs FDA: Key Differences](/blog/mdr-vs-fda-key-differences-eu-us-medical-device-regulation) — the quick comparison companion to this deeper structural piece.
- [FDA 510(k) vs MDR CE Marking](/blog/fda-510k-vs-mdr-ce-marking) — the two dominant pathways side by side.
- [Dual Submission Strategy](/blog/dual-submission-strategy-ce-fda) — planning one product through two pathways.
- [Regulatory Strategy for Startups Targeting EU and US](/blog/regulatory-strategy-startups-targeting-eu-us-markets) — strategic sequencing for small teams.
- [FDA QSR to QMSR Transition](/blog/fda-qsr-qmsr-transition-2026) — how US quality expectations are aligning with ISO 13485.

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Article 5, Annex VIII, Annex IX, Annex X, Annex XI.
2. EN ISO 13485:2016+A11:2021 — Medical devices — Quality management systems — Requirements for regulatory purposes.
3. Federal Food, Drug, and Cosmetic Act, and Title 21 of the Code of Federal Regulations, Parts 800-898 — general reference for FDA medical device regulation structure.

---

*This post is part of the [FDA & International Market Access](https://zechmeister-solutions.com/en/blog/category/fda-international) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*